Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9.
Collaborators, Affiliations
- PMID: 31189517
- DOI: 10.1016/S2213-8587(19)30192-5
Free article
Clinical Trial
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al. Lancet Diabetes Endocrinol. 2019 Jul.
Free article
Erratum in
- Correction to Lancet Diabetes Endocrinol 2019; 7: 515-27.
[No authors listed] [No authors listed] Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21. doi: 10.1016/S2213-8587(19)30246-3. Epub 2019 Jul 15. Lancet Diabetes Endocrinol. 2019. PMID: 31320281 No abstract available.
Abstract
Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We aimed to investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment.
Methods: This randomised, double-blind, phase 3a trial was undertaken at 88 sites in eight countries. Patients aged 18 years and older, with type 2 diabetes, an estimated glomerular filtration rate of 30-59 mL/min per 1·73 m2, and who had been receiving a stable dose of metformin or sulfonylurea, or both, or basal insulin with or without metformin for the past 90 days were eligible. Participants were randomly assigned (1:1) by use of an interactive web-response system, with stratification by glucose-lowering medication and renal function, to receive oral semaglutide (dose escalated to 14 mg once daily) or matching placebo for 26 weeks, in addition to background medication. Participants and site staff were masked to assignment. Two efficacy-related estimands were defined: treatment policy (regardless of treatment discontinuation or rescue medication) and trial product (on treatment without rescue medication) in all participants randomly assigned. Endpoints were change from baseline to week 26 in HbA1c (primary endpoint) and bodyweight (confirmatory secondary endpoint), assessed in all participants with sufficient data. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered on ClinicalTrials.gov, number NCT02827708, and the European Clinical Trials Registry, number EudraCT 2015-005326-19, and is now complete.
Findings: Between Sept 20, 2016, and Sept 29, 2017, of 721 patients screened, 324 were eligible and randomly assigned to oral semaglutide (n=163) or placebo (n=161). Mean age at baseline was 70 years (SD 8), and 168 (52%) of participants were female. 133 (82%) participants in the oral semaglutide group and 141 (88%) in the placebo group completed 26 weeks on treatment. At 26 weeks, oral semaglutide was superior to placebo in decreasing HbA1c (estimated mean change of -1·0 percentage point (SE 0·1; -11 mmol/mol [SE 0·8]) vs -0·2 percentage points (SE 0·1; -2 mmol/mol [SE 0·8]); estimated treatment difference [ETD]: -0·8 percentage points, 95% CI -1·0 to -0·6; p<0·0001) and bodyweight (estimated mean change of -3·4 kg [SE 0·3] vs -0·9 kg [SE 0·3]; ETD, -2·5, 95% CI -3·2 to -1·8; p<0·0001) by the treatment policy estimand. Significant differences were seen for the trial product estimand: mean change in HbA1c -1·1 percentage points (SE 0·1; -12 mmol/mol [SE 0·8] versus -0·1 percentage points (SE 0·1; -1 mmol/mol [SE 0·8]; ETD -1·0 percentage points, 95% CI -1·2 to -0·8; p<0·0001); mean change in bodyweight -3·7 kg (SE 0·3) versus -1·1 kg (SE 0·3; ETD -2·7 kg, 95% CI -3·5 to -1·9; p<0·0001). More patients taking oral semaglutide than placebo had adverse events (120 [74%] of 163 vs 105 [65%] of 161), and discontinued treatment as a result (24 [15%] vs eight [5%]). Gastrointestinal events, mainly mild-to-moderate nausea, were more common with oral semaglutide than with placebo. Three deaths occurred during the treatment period that were not condsidered to be treatment related, one in the semaglutide group and two in the placebo group.
Interpretation: Oral semaglutide was effective in patients with type 2 diabetes and moderate renal impairment, potentially providing a new treatment option for this population. Safety, including renal safety, was consistent with the GLP-1 receptor agonist class.
Funding: Novo Nordisk A/S.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
- Pioneering oral peptide therapy for patients with type 2 diabetes.
Nauck MA, Meier JJ. Nauck MA, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):500-502. doi: 10.1016/S2213-8587(19)30182-2. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189516 No abstract available. - T2DM treatment trial results.
Greenhill C. Greenhill C. Nat Rev Endocrinol. 2019 Sep;15(9):499. doi: 10.1038/s41574-019-0234-2. Nat Rev Endocrinol. 2019. PMID: 31253858 No abstract available.
Similar articles
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ; PIONEER 4 investigators. Pratley R, et al. Lancet. 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. Lancet. 2019. PMID: 31186120 Clinical Trial. - Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB; PIONEER 7 investigators. Pieber TR, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189520 Clinical Trial. - Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB. Frías JP, et al. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34293304 Clinical Trial. - Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
Mosenzon O, Miller EM, Warren ML. Mosenzon O, et al. Postgrad Med. 2020 Nov;132(sup2):37-47. doi: 10.1080/00325481.2020.1800286. Epub 2020 Sep 8. Postgrad Med. 2020. PMID: 32815439 Review. - Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Karagiannis T, et al. Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17. Diabetologia. 2022. PMID: 35579691 Free PMC article. Review.
Cited by
- PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
Saravanan P, Bell H, Braae UC, Collins E, Deinega A, Dhatariya K, Machell A, Trent A, Strzelecka A. Saravanan P, et al. Adv Ther. 2024 Sep 24. doi: 10.1007/s12325-024-02973-z. Online ahead of print. Adv Ther. 2024. PMID: 39316289 - Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
Marques Vidas M, López-Sánchez P, Sánchez-Briales P, López Illazquez MV, Portolés J. Marques Vidas M, et al. J Clin Med. 2024 Aug 30;13(17):5166. doi: 10.3390/jcm13175166. J Clin Med. 2024. PMID: 39274378 Free PMC article. - Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.
Pantanetti P, Ronconi V, Sguanci M, Palomares SM, Mancin S, Tartaglia FC, Cangelosi G, Petrelli F. Pantanetti P, et al. J Clin Med. 2024 Aug 13;13(16):4752. doi: 10.3390/jcm13164752. J Clin Med. 2024. PMID: 39200893 Free PMC article. - Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study.
Sato G, Uchino H, Hirose T. Sato G, et al. Diabetes Ther. 2024 Sep;15(9):2119-2130. doi: 10.1007/s13300-024-01631-5. Epub 2024 Aug 7. Diabetes Ther. 2024. PMID: 39110375 Free PMC article. - Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.
Masson W, Lobo M, Nogueira JP, Rodriguez-Granillo AM, Barbagelata LE, Siniawski D. Masson W, et al. Front Cardiovasc Med. 2024 Jul 5;11:1379189. doi: 10.3389/fcvm.2024.1379189. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39055657 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous